Tests N-acetylcysteine for repetitive behaviors in children with autism
Tests N-acetylcysteine, a supplement, for repetitive behaviors in children with autism.
Plain-language title generated from the registry record
Registry title: Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Open Label
Key facts
- Where
- Stanford, United StatesSee the site
- Phase
- Phase 2/3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 3 and 13 years old?
Source: NCT05494398, who can take part
Where in United States
- Stanford University School of MedicineStanford, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Stanford University
- Trial code
- NCT05494398
- Record updated
- 15 May 2026
- Original description
The goal of this study is to target the neurobiology of restricted and repetitive behaviors in children with autism spectrum disorder using N-acetylcysteine (NAC), a well-tolerated nutritional supplement that has shown promise for reducing symptom severity in recent small-scale trials. The findings from this research will shed light on the mechanisms of action underlying the clinical benefits of NAC and the effects of NAC on altering restricted and repetitive behavior symptom severity in children with autism spectrum disorder.Read full original descriptionShow less
Targeting the Neurobiology of Restricted and Repetitive Behaviors in Children With Autism Using N-acetylcysteine: an Open Label Extension
The goal of this study is to target the neurobiology of restricted and repetitive behaviors in children with autism spectrum disorder using N-acetylcysteine (NAC), a well-tolerated nutritional supplement that has shown promise for reducing symptom severity in recent small-scale trials. The findings from this research will shed light on the mechanisms of action underlying the clinical benefits of NAC and the effects of NAC on altering restricted and repetitive behavior symptom severity in children with autism spectrum disorder.
Inclusion: participation in an associated single-dose (IRB-54931, NCT04278898) or randomized, controlled trial of NAC (IRB- 68353, NCT05664789); stable medication regimens (≥ 30 days) with no anticipated changes during the trial.
Exclusion: the presence of significant medical problems that reduce medical stability.